Euclid Vision Names Dr. Zohra Fadli, as Global Head of R&D and Clinical Affairs

May 16, 2022

The vision care veteran’s appointment to the top R&D role is a reflection of Euclid’s ongoing commitment to innovation.

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce the appointment of Zohra Fadli, PhD, to the position of vice president of research and development & clinical affairs. Dr. Fadli brings decades of experience in medical device technology and vision care to her new role at Euclid, including an extensive history in delivering breakthrough ophthalmic contact lenses.

For close to 20 years, Dr. Fadli held global leadership roles in Johnson and Johnson’s (J&J) medical technology divisions. She led the J&J Vision Care Light Management Portfolio, launching a first of its kind light adaptive photochromic contact lens which was named by Time magazine as one of the best inventions in 2018.

Welcome Dr. Zohra Fadli to Euclid |
Dr. Fadli also led J&J’s core contact lens business including sphere daily disposable, reusable, and lens care where she played an integral role in setting up the innovation, pipeline, and development of J&J’s first monthly silicone hydrogel reusable contact lens. Dr. Fadli expanded her responsibilities to lead J&J Vision care Specialty Growth Business including Myopia Progression platform, Presbyopia, and Beauty Platforms. She also pioneered J&J vision care global evidence generation strategy aimed to generate best in class clinical and technical scientific evidence in support of new product innovations. Finally, Dr. Fadli also lead the R&D strategy and operations team for J&J orthopedic surgical franchise. Dr. Fadli holds a PhD in Medical Bioengineering from Université Paris 13, France.

Euclid Max |
Dr. Fadli’s timely appointment to the R&D role is a key step in Euclid’s continued expansion. Euclid recently acquired the scleral contact lens pioneer, Visionary Optics; and prior to that introduced Euclid MAX™ — Euclid’s newest Ortho-K lens that has outstanding material characteristics, providing excellent wettability, oxygen permeability, and lens stability. Euclid’s ongoing commitment to innovation and Dr. Fadli’s involvement in the development of groundbreaking innovation across the vision care spectrum suggest exciting times ahead for the company.

Commenting on the appointment, Joseph Boorady, Euclid President and CEO said, “We are excited to bring Dr. Fadli on board at this pivotal time in Euclid’s evolution. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses—positions Euclid to best serve our customers today; and having Dr. Fadli heading up R&D, positions us to anticipate and satisfy patient needs tomorrow and in the coming years.”

* Based on internal date